Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03351842
Other study ID # K17-151
Secondary ID
Status Recruiting
Phase Phase 2
First received November 20, 2017
Last updated December 17, 2017
Start date September 1, 2017
Est. completion date September 1, 2024

Study information

Verified date December 2017
Source Shanghai Pulmonary Hospital, Shanghai, China
Contact Yingran Shen, PhD
Phone 86-18117166317
Email elaineshen91@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Randomized phase II trial aims to compare surgery with or without adjuvant chemotherapy in treating patients who are pathologically diagnosed as stage I lung adenocarcinoma with micropapillary component no less than 20%.


Description:

The presence of micropapillary component in adenocarcinoma is a predictor of poor prognosis, and has been reported to be to be chemosensitive to platinum-based chemotherapy. Seeking a more appropriate treatment for these patients, we perform this randomized phase II clinical trial. About 460 stage I lung adenocarcinoma patients with micropapillary component ≥ 20% will be included and divided into two group. Patients in the control group will only undergo complete R0 resection of the lesion, no further therapy will be used. While patients in the experimental group are going to receive platinum-based chemotherapy (comprising cisplatin and pemetrexed disodium)about 1 month after therapeutic surgery. Treatment continues every 3 weeks for 4 courses. Clinic and telephone follow up will be conducted for survival data monitoring.

DFS(disease free survival rate) and OS(overall survival rate) curves will be calculated using the Kaplan-Meier, life-table method. Comparison of the survival curve for the two groups will be performed using the log-rank test.


Recruitment information / eligibility

Status Recruiting
Enrollment 460
Est. completion date September 1, 2024
Est. primary completion date September 1, 2019
Accepts healthy volunteers No
Gender All
Age group 19 Years to 70 Years
Eligibility Inclusion Criteria:

- Completely resected Stage I NSCLC as defined by the International Staging System

- Pathologically diagnosed Stage I micropapillary predominant lung adenocarcinoma

- Patients must be randomized within 4 weeks from the date of surgery

- No prior chemotherapy or radiation for non-small cell lung cancer

- Performance status of 0 or 1

- Women must be non-pregnant and non-lactating; patients of childbearing potential must agree to use an effective form of contraception while on study

- Patients must have no history of previous or concomitant malignancy, other than curatively treated carcinoma in situ of the cervix, or basal cell or squamous cell carcinoma of the skin, or surgically treated in situ carcinoma of the breast, or other cancer for which the patient has been disease free for five years

- Granulocytes >= 1,800/ul

- Platelets >= 100,000/ul

- Bilirubin < 1.5 mg/dl

- SGOT(serum glutamic-oxaloacetic transaminase) (AST) < 2.0 x ULN(upper limit of normal value)

Exclusion Criteria:

- Do not meet the inclusion criteria

- There is evidence of distant metastases

- Suffered from other malignancies in five years

- Within the past January subjects received other drug trials

- Having serious allergies or idiosyncratic persons, such as you can not use folic acid, dexamethasone, vitamin B12 patients

- Severe lung or heart disease, a history

- Refuses or is unable to sign informed consent to participate in trials

- The abuse of drugs or alcohol addicts.

- Patients with difficult to control bacterial, viral, fungal infections

- Having a personality or mental disorders, without civil capacity or restricted civil capacity.

- Being pregnant or lactating women.

Study Design


Intervention

Drug:
cis Platinum/Carboplatin, Pemetrexed Disodium
Intravenous inject Pemetrexed Disodium for Injection over 10 minutes, waiting for at least 30 minutes, then followed by cis Platinum/ Carboplatin over 2 hours
Procedure:
Undergo surgery
Therapeutic conventional surgery, R0 resection

Locations

Country Name City State
China Thoracic Surgery Department of Shanghai Pulmonary Hospital Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Shanghai Pulmonary Hospital, Shanghai, China

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Disease-Free-Survival-Rate the percentage of people in the trial who are alive and cancer free after a specified number of years up to 60 months
Secondary Overall-Survival-Rate the percentage of people in the trial who alive, with or without signs of cancer up to 60 months
Secondary Disease-Free-Survival-Time From date of diagnosis until the date of first documented progression or date of cancer related death , whichever came first up to 60 months
Secondary Overall-Survival-Time Time from randomization until death from any cause up to 60 months
See also
  Status Clinical Trial Phase
Recruiting NCT05243134 - The Influence of Anatomic Deformities on the Clinical Efficacy in the Patients With Patellar Dislocation
Completed NCT02486874 - Clinical Evaluation of PoreSkin Phase 1
Active, not recruiting NCT04592640 - Stem Cells for Uremic Calciphylaxis Patients N/A
Recruiting NCT04599686 - Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Prostate Cancer N/A
Completed NCT03439930 - The Effect of Balance Training on Neuromuscular Control in Subjects With CAI N/A
Completed NCT02782442 - Cognitive Training Delivered Remotely to Individuals With Psychosis (ROAM) N/A
Not yet recruiting NCT05537155 - Buccal Acupuncture for Delirium Treatment in Older Patients Recovering From Orthopedic Surgery N/A
Recruiting NCT02971982 - PCD Versus RCD for the Treatment of Patients With Waldenstrom's Macroglobulinemia Phase 1/Phase 2
Completed NCT02820272 - Water for Reducing Pain in Negative Pressure Wound Therapy Phase 2
Completed NCT00984958 - Bulkamid Treatment of Stress Incontinence in Women With Urinary Stress Incontinence and Not Suitable to TVT-procedure N/A
Completed NCT00575224 - Pegasys and Copegus for Asian Patients With Treatment-naive Hepatitis C Genotypes 6, 7, 8, 9 Phase 4
Completed NCT00164528 - Intervening With Children/Adolescents With FAS/ARND Phase 1/Phase 2
Completed NCT00164307 - Assisting Children With Prenatal Alcohol Exposure in Developing Peer Friendships Phase 1/Phase 2
Recruiting NCT04603586 - Stereotactic Radiotherapy in Locally Advanced Pancreatic Cancer With Different Biological Effective Doses N/A
Recruiting NCT03375424 - Vedolizumab Study With Inflammatory Bowel Disease Patients in Germany N/A
Not yet recruiting NCT04062370 - Ranibizumab Treatment for Macular Edema Secondary to Retinal Vein Occlusion Phase 4
Not yet recruiting NCT02931136 - Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging Phase 4
Completed NCT04661228 - Diagnostic Survey of Mental and Substance Use Disorders in HUNT (PsykHUNT)
Recruiting NCT03365141 - Efficacy of Intralesional Triamcinolone Injection in the Treatment of Vitiligo N/A
Recruiting NCT04599699 - Integrated Boost to the Dominant Intraprostatic Nodule Based on Ga-68 PSMA PET/MR Study of SBRT With Prostate Cancer N/A